Shane A. Olwill

1.0k total citations
28 papers, 691 citations indexed

About

Shane A. Olwill is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Shane A. Olwill has authored 28 papers receiving a total of 691 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 12 papers in Radiology, Nuclear Medicine and Imaging and 9 papers in Molecular Biology. Recurrent topics in Shane A. Olwill's work include Monoclonal and Polyclonal Antibodies Research (11 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and CAR-T cell therapy research (6 papers). Shane A. Olwill is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (11 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and CAR-T cell therapy research (6 papers). Shane A. Olwill collaborates with scholars based in United Kingdom, United States and Netherlands. Shane A. Olwill's co-authors include Christopher J. Scott, Roberta E. Burden, Julie A. Gormley, Derek J. Quinn, Thomas J. Jaquin, James A. Johnston, Paul A. McCarron, François Fay, H. Denis Alexander and William Gilmore and has published in prestigious journals such as PLoS ONE, Cancer Research and Clinical Cancer Research.

In The Last Decade

Shane A. Olwill

28 papers receiving 676 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shane A. Olwill United Kingdom 15 266 190 186 125 95 28 691
Donna M. Small United Kingdom 16 283 1.1× 213 1.1× 156 0.8× 59 0.5× 59 0.6× 28 763
Andrey S. Dobroff United States 21 761 2.9× 171 0.9× 236 1.3× 134 1.1× 67 0.7× 35 1.2k
Yeup Yoon South Korea 18 524 2.0× 205 1.1× 102 0.5× 47 0.4× 135 1.4× 38 900
Wen-Wei Lin Taiwan 17 307 1.2× 64 0.3× 147 0.8× 122 1.0× 31 0.3× 56 689
Fazel Shokri Iran 16 518 1.9× 76 0.4× 273 1.5× 172 1.4× 65 0.7× 71 1.1k
Yingchun Hou China 18 769 2.9× 324 1.7× 206 1.1× 92 0.7× 107 1.1× 49 1.1k
Kevin L. Bicker United States 16 654 2.5× 110 0.6× 168 0.9× 107 0.9× 70 0.7× 21 1.1k
Roya Ghods Iran 16 551 2.1× 128 0.7× 277 1.5× 109 0.9× 46 0.5× 72 1.0k
Sihe Zhang China 16 636 2.4× 158 0.8× 152 0.8× 51 0.4× 103 1.1× 49 913
Diana Brassard United States 13 382 1.4× 67 0.4× 321 1.7× 133 1.1× 189 2.0× 17 1.1k

Countries citing papers authored by Shane A. Olwill

Since Specialization
Citations

This map shows the geographic impact of Shane A. Olwill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shane A. Olwill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shane A. Olwill more than expected).

Fields of papers citing papers by Shane A. Olwill

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shane A. Olwill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shane A. Olwill. The network helps show where Shane A. Olwill may publish in the future.

Co-authorship network of co-authors of Shane A. Olwill

This figure shows the co-authorship network connecting the top 25 collaborators of Shane A. Olwill. A scholar is included among the top collaborators of Shane A. Olwill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shane A. Olwill. Shane A. Olwill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Matschiner, Gabriele, Mary Fitzgerald, Ulrich Moebius, et al.. (2022). Elarekibep (PRS-060/AZD1402), a new class of inhaled Anticalin medicine targeting IL-4Ra for type 2 endotype asthma. Journal of Allergy and Clinical Immunology. 151(4). 966–975. 11 indexed citations
3.
Pattarini, Lucia, et al.. (2022). Abstract LB220: The anticalin-antibody bispecific PRS-352/S095025 strongly stimulates human CD4+ T cells in a PD-L1-dependent manner. Cancer Research. 82(12_Supplement). LB220–LB220. 1 indexed citations
4.
Wurzenberger, Claudia, Cornelia Wurzenberger, Stefan Grüner, et al.. (2021). Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF. PA732–PA732. 3 indexed citations
5.
Ku, Geoffrey Y., A. W. Tolcher, Sara A. Hurvitz, et al.. (2020). 525O A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies. Annals of Oncology. 31. S462–S463. 26 indexed citations
6.
Piha‐Paul, Sarina A., Johanna C. Bendell, Sara A. Hurvitz, et al.. (2020). O82 A phase 1 dose escalation study of PRS-343, a HER2/4–1BB bispecific molecule, in patients with HER2-positive malignancies. Oral Presentations. A1.2–A2. 30 indexed citations
7.
Hohlbaum, Andreas M., Hendrik Gille, Stefan Trentmann, et al.. (2018). Sustained plasma hepcidin suppression and iron elevation by Anticalin‐derived hepcidin antagonist in cynomolgus monkey. British Journal of Pharmacology. 175(7). 1054–1065. 28 indexed citations
8.
Hinner, Marlon J., Corinna Schlosser, Thomas J. Jaquin, et al.. (2016). Abstract B016: Costimulatory T-cell engagement by PRS-343, a CD137 (4-1BB)/HER2 bispecific, leads to tumor growth inhibition and TIL expansion in humanized mouse model. Cancer Immunology Research. 4(11_Supplement). B016–B016. 1 indexed citations
9.
Scheltinga, Anton G.T. Terwisscha van, Marjolijn N. Lub–de Hooge, Marlon J. Hinner, et al.. (2014). In Vivo Visualization of MET Tumor Expression and Anticalin Biodistribution with the MET-Specific Anticalin 89Zr-PRS-110 PET Tracer. Journal of Nuclear Medicine. 55(4). 665–671. 39 indexed citations
10.
Olwill, Shane A., Hendrik Gille, Elisa Vigna, et al.. (2013). A Highly Potent and Specific MET Therapeutic Protein Antagonist with Both Ligand-Dependent and Ligand-Independent Activity. Molecular Cancer Therapeutics. 12(11). 2459–2471. 25 indexed citations
11.
Shuralev, Eduard A., Mairead B. Doyle, Anthony Duignan, et al.. (2011). Application of the Enfer chemiluminescent multiplex ELISA system for the detection of Mycobacterium bovis infection in goats. Veterinary Microbiology. 154(3-4). 292–297. 14 indexed citations
12.
Camper, N. D., Roberta E. Burden, James A. Johnston, et al.. (2011). Stable expression and purification of a functional processed Fab′ fragment from a single nascent polypeptide in CHO cells expressing the mCAT-1 retroviral receptor. Journal of Immunological Methods. 372(1-2). 30–41. 6 indexed citations
13.
Burden, Roberta E., Julie A. Gormley, Hang Fai Kwok, et al.. (2011). Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas. Biochimie. 94(2). 487–493. 47 indexed citations
14.
Gormley, Julie A., Shauna Hegarty, A O’Grady, et al.. (2011). The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study. British Journal of Cancer. 105(10). 1487–1494. 60 indexed citations
15.
Burden, Roberta E., Julie A. Gormley, Thomas J. Jaquin, et al.. (2010). Antibody Targeting of Cathepsin S Inhibits Angiogenesis and Synergistically Enhances Anti-VEGF. PLoS ONE. 5(9). e12543–e12543. 54 indexed citations
16.
17.
Burden, Roberta E., Julie A. Gormley, Thomas J. Jaquin, et al.. (2009). Antibody-Mediated Inhibition of Cathepsin S Blocks Colorectal Tumor Invasion and Angiogenesis. Clinical Cancer Research. 15(19). 6042–6051. 87 indexed citations
18.
Olwill, Shane A., Hugh McGlynn, William Gilmore, & H. Denis Alexander. (2005). All‐trans retinoic acid‐induced downregulation of annexin II expression in myeloid leukaemia cell lines is not confined to acute promyelocytic leukaemia. British Journal of Haematology. 131(2). 258–264. 16 indexed citations
19.
Olwill, Shane A., Hugh McGlynn, William Gilmore, & H. Denis Alexander. (2004). Annexin II cell surface and mRNA expression in human acute myeloid leukaemia cell lines. Thrombosis Research. 115(1-2). 109–114. 20 indexed citations
20.
Gilmore, William, et al.. (2004). Annexin A2 expression during cellular differentiation in myeloid cell lines. Biochemical Society Transactions. 32(6). 1122–1123. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Donna M. Small Breakdown of academic impact, for papers by Andrey S. Dobroff Breakdown of academic impact, for papers by Yeup Yoon Breakdown of academic impact, for papers by Wen-Wei Lin Breakdown of academic impact, for papers by Fazel Shokri Breakdown of academic impact, for papers by Yingchun Hou Breakdown of academic impact, for papers by Kevin L. Bicker Breakdown of academic impact, for papers by Roya Ghods Breakdown of academic impact, for papers by Sihe Zhang Breakdown of academic impact, for papers by Diana Brassard
Rankless by CCL
2026